Why Healthcare Is Getting More Expensive—and Why That Shouldn’t Surprise Us
Why Healthcare Is Getting More Expensive—and Why That Shouldn’t Surprise Us
Healthcare costs are rising, and nearly every discussion about that fact quickly turns to blame—governments, insurers, pharmaceutical companies, or providers. While there are certainly policy, market, and structural factors that contribute to higher costs, there is a more fundamental driver that receives far less attention: scientific progress itself.
From a purely scientific perspective, rising healthcare costs are not just possible—they are predictable.
The Low-Hanging Fruit of the 20th Century
Over the course of the 20th century, medicine made enormous gains by addressing the simplest, broadest, and most cost-effective interventions first. Public sanitation, clean water, vaccines, antibiotics, basic surgical techniques, and widely effective small-molecule medications dramatically improved population health at relatively low cost.
These advances worked because they:
Addressed common conditions
Required limited specialization
Could be scaled to large populations
Delivered outsized benefit for relatively modest investment
In other words, medicine spent much of the last century harvesting the lowest-hanging fruit.
What Comes After the Easy Wins
As science advances, what remains are problems that are inherently harder to solve.
Modern medical innovation increasingly targets:
Rare diseases
Complex biological pathways
Conditions requiring personalized or precision-based approaches
Patients who failed existing therapies
These advances naturally require more sophisticated research, specialized expertise, complex manufacturing, and smaller eligible populations. All of those factors drive cost upward—even before questions of pricing strategy or reimbursement enter the discussion.
Some rising healthcare costs are avoidable. Others are simply the price of progress.
Pharmacy as a Case Study in Scientific Complexity
The evolution of drug development illustrates this trend clearly.
Many of the small-molecule drugs with the greatest population-level impact—antibiotics, antihypertensives, statins, oral antidiabetics—were discovered decades ago. They remain incredibly valuable, but the pipeline of similarly transformative, low-cost small molecules has narrowed.
There are notable exceptions. GLP-1 receptor agonists, for example, demonstrate that impactful pharmacologic breakthroughs are still possible. But they are increasingly rare.
Over the past 25 years, a growing share of new therapies have been biologics, particularly monoclonal antibodies. These drugs are:
More expensive to develop
More complex to manufacture
Often indicated for narrower patient populations
Looking ahead, gene therapies and cell-based treatments are expected to play an even larger role. These interventions may offer curative potential—but at costs that dwarf traditional pharmacotherapy.
This is not a failure of the system. It is a reflection of scientific reality.
Why Cost Growth Is Not the Same as Waste
Acknowledging the scientific drivers of cost growth does not mean accepting inefficiency or excess.
Governments, insurers, and manufacturers still have an obligation to:
Evaluate value rigorously
Promote competition where possible
Use evidence-based coverage policies
Invest in cost-reduction strategies without undermining innovation
But it is important to distinguish between avoidable waste and unavoidable complexity. Treating all cost growth as evidence of failure leads to blunt policy tools that can restrict access, delay care, or discourage innovation.
A Historical Perspective Matters
Seen through a longer lens, today’s costs should not be surprising.
The medicines of 2025 are more expensive than those of 2000.
Those of 2000 were more expensive than those of 1975.
And those of 1975 were more expensive than those of 1950.
Each generation of therapy reflects deeper scientific understanding, greater technical sophistication, and higher expectations of what medicine can achieve.
The Challenge Ahead
The real challenge for healthcare systems is not to deny this reality, but to manage it responsibly. That means:
Aligning payment with clinical value
Making difficult coverage decisions transparently
Investing in prevention and public health where costs remain low
Accepting that not every breakthrough will be inexpensive
Healthcare can—and should—strive to be more efficient. But rising costs driven by genuine scientific advancement are not a sign that medicine has gone wrong. In many cases, they are evidence that it has gone further.
Understanding that distinction is essential if we want policy debates about healthcare costs to be grounded in reality rather than frustration.
